Date: 2015-03-30
Type of information: Collaboration agreement
Compound: chimeric antigen receptor T-cell (CAR-T) products
Company: Ziopharm Oncology (USA - MA) Intrexon (USA - MD) Merck KGaA (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration R&D
Action mechanism: immunotherapy product/cell therapy/gene therapy.
Disease:
Details: * On March 30, 2015, Ziopharm Oncology and Intrexon announced their oncology programs will be strengthened through Intrexon\'s new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with Ziopharm. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreement with Intrexon, Ziopharm will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug (IND) stage, the programs will be transferred to Merck Serono for clinical development and commercialization. Ziopharm and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. Ziopharm\'s other oncology programs will continue through its Exclusive Channel Collaboration (ECC) with Intrexon.
Financial terms:
Latest news:
